Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Stacey Kowal"'
Autor:
Abigail G. Riley, Christina M. Mulé, Debra Lerner, Lisa Belter, Colleen McCarthy O’Toole, Stacey Kowal, David Fox, Sheila Shapouri, Tamara Vesel, Tara A. Lavelle
Publikováno v:
Cost Effectiveness and Resource Allocation, Vol 21, Iss 1, Pp 1-9 (2023)
Abstract Background U.S. cost-effectiveness recommendations suggest that analyses should include all costs and effects relevant to the decision problem [1]. However, in many diseases, including spinal muscular atrophy (SMA), few studies have evaluate
Externí odkaz:
https://doaj.org/article/fb222626009b41ca9501143ac5f4da72
Publikováno v:
Value in Health. 26:216-225
We conducted a distributional cost-effectiveness analysis (DCEA) to evaluate how Medicare funding of inpatient COVID-19 treatments affected health equity in the United States.A DCEA, based on an existing cost-effectiveness analysis model, was conduct
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c20d5a53ea365837566c343c4ff67445
https://doi.org/10.1016/j.jval.2022.08.010
https://doi.org/10.1016/j.jval.2022.08.010
Publikováno v:
Applied Health Economics and Health Policy. 21:305-314
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e22f784d40560c0068bb243f0cb8f9be
https://doi.org/10.1007/s40258-022-00779-0
https://doi.org/10.1007/s40258-022-00779-0
Publikováno v:
Value in Health. 25:1878-1884
This study aimed to provide recommendations for identifying and implementing real option value (ROV) calculations in value assessment.We identified the primary mechanisms through which ROV can be created based on a theoretical framework for ROV, asse
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d37960b4e1e4ed4e4f0728b2cb608cb6
https://doi.org/10.1016/j.jval.2022.05.014
https://doi.org/10.1016/j.jval.2022.05.014
Publikováno v:
Journal of managed carespecialty pharmacy. 28(7)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::79d2cc6628ce2f003bf36c23ddb2dd7b
https://pubmed.ncbi.nlm.nih.gov/35737862
https://pubmed.ncbi.nlm.nih.gov/35737862
Autor:
Jürgen Wolf, Jacoline C. Bouvy, Oriol Sola-Morales, Richard H. Chapman, Andrew Briggs, Carsten Bokemeyer, Jennifer G. Gaultney, Alexander J Upton, Stacey Kowal
Publikováno v:
Applied Health Economics and Health Policy. 19:625-634
The arrival of precision oncology is challenging the evidence standards under which technologies are evaluated for regulatory approval as well as for health technology assessment (HTA) purposes. Several key concepts are discussed to highlight the sou
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6cb7034e5045235c20081efea00f8147
https://doi.org/10.1007/s40258-021-00654-4
https://doi.org/10.1007/s40258-021-00654-4
Autor:
Marquita Decker-Palmer, Chia-Wei Lin, Michele Wilson, Cheryl McDade, Komal Bawa, Stacey Kowal, Arliene Ravelo, Elaine Yu, Richard H. Ko
Publikováno v:
Blood. 140:13041-13042
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::87279510a921cc3dad0529a71b124330
https://doi.org/10.1182/blood-2022-162276
https://doi.org/10.1182/blood-2022-162276
Publikováno v:
PharmacoEconomics. 40(6)
A drug that improves survival and/or disease progression can create real option value (ROV)-the additional health gain from future innovations enabled by a longer survival. ROV can be a relevant consideration for both clinical and payer decision-make
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::756eacf3282015a6d21ec6ba04cdee8d
https://pubmed.ncbi.nlm.nih.gov/35527331
https://pubmed.ncbi.nlm.nih.gov/35527331
Autor:
Aurelie Meunier, Louise Longworth, Stacey Kowal, Sreeram Ramagopalan, James Love-Koh, Susan Griffin
Publikováno v:
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
Governments and health technology assessment agencies are putting greater focus on and efforts in understanding and addressing health inequities. Cost-effectiveness analyses are used to evaluate the costs and health gains of different interventions t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::00cdb1e1655defc5d5c87dbf8fddef18
https://pubmed.ncbi.nlm.nih.gov/35941004
https://pubmed.ncbi.nlm.nih.gov/35941004
Autor:
Christina Ciaccio, Jessica Dunne, Andrea Bever, Alexis Mickle, Stacey Kowal, Arpamas Seetasith, Andrew Lloyd, Karissa Johnston
Publikováno v:
Journal of Allergy and Clinical Immunology. 151:AB99
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3273f02e99e48f875217b5100ebae10c
https://doi.org/10.1016/j.jaci.2022.12.317
https://doi.org/10.1016/j.jaci.2022.12.317